PD-1抑制剂治疗的转移性肺癌患者腹部免疫相关不良事件的发生率与影像学特征
回顾性纳入137例接受纳武利尤单抗单药治疗的转移性非小细胞肺癌患者,复查腹部CT发现18例(13%)出现腹部免疫相关不良事件,中位发生时间2.1个月;最常见为全结肠炎型结肠炎/小肠结肠炎,CT特征包括肠系膜充血、肠壁增厚、黏膜明显强化和结肠积液。
要点
- 纳武利尤单抗治疗中约13%患者CT可检出腹部免疫相关不良事件,中位出现于用药后2.1个月。
- 结肠炎/小肠结肠炎最常见,多为全结肠炎型,CT可见肠系膜充血、肠壁增厚、黏膜强化和结肠积液。
- 部分腹部不良事件在停用纳武利尤单抗后、后续治疗开始前出现,可促使中断用药并予激素治疗。
核心结论
- 接受纳武利尤单抗治疗的转移性非小细胞肺癌患者中,13%经CT检出腹部免疫相关不良事件,全结肠炎型结肠炎最常见;放射科医生应了解其发生率和影像表现及其对患者管理的影响。
研究设计与样本
- 回顾性研究,纳入137例接受PD-1抑制剂纳武利尤单抗单药治疗的转移性非小细胞肺癌患者(75例女性,中位年龄65岁),均有基线CT及治疗期间至少一次腹部随访CT。
关键影像表现/征象
- 结肠炎/小肠结肠炎最常见CT特征为肠系膜充血(15例)。
- 肠壁增厚见于13例。
- 黏膜明显强化见于10例。
- 结肠积液见于9例。
诊断标准与关键数值
- 18例(13%)患者检出腹部免疫相关不良事件,中位发生时间为开始纳武利尤单抗后2.1个月(四分位距1.17–5.83个月)。
- 16例发生小肠结肠炎/结肠炎(12例全结肠炎、2例节段性结肠炎、1例小肠结肠炎、1例小肠炎),2例肝炎,1例肾上腺炎。
- 1例肝炎患者同时发生结肠炎/小肠结肠炎。
- 6例患者在停用纳武利尤单抗后、后续治疗开始前出现影像学腹部免疫相关不良事件。
- 4例(3例结肠炎/小肠结肠炎、1例肝炎)因免疫相关不良事件中断纳武利尤单抗并接受激素治疗。
临床应用与阅片要点
- 放射科医生阅片时应了解接受纳武利尤单抗治疗的转移性非小细胞肺癌患者腹部免疫相关不良事件的发生率与影像表现,及其对患者管理的影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To investigate the frequency and imaging features of radiographically evident abdominal immune-related adverse events (irAEs) in patients with metastatic non-small-cell lung cancer (NSCLC) treated with PD-1 inhibitors.
METHODS: This retrospective study included 137 patients with metastatic NSCLC treated with PD-1 inhibitor nivolumab monotherapy (75 women; median age: 65 years), who had a baseline CT and at least one follow-up abdomen CT during therapy. Baseline and all follow-up abdominal CTs performed for monitoring of nivolumab therapy were reviewed to identify the organ-specific abdominal irAEs including colitis/enteritis, hepatitis, biliary toxicity, pancreatitis, nephritis, sarcoid-like reaction, and pancreatic and adrenal atrophy. Their frequency and imaging features were described.
RESULTS: Eighteen (13%) patients had radiologically identified abdominal irAEs (median 2.1 months after starting nivolumab; interquartile range 1.17-5.83 months); 16 patients developed enteritis/colitis (12 pancolitis, two segmental colitis, one enterocolitis, one enteritis), two hepatitis, one adrenalitis. One patient with hepatitis also developed colitis/enteritis. Radiographic abdominal irAE occurred after nivolumab therapy was discontinued in six patients before any subsequent therapy was started. IrAEs prompted nivolumab interruption and treatment with steroids in four patients (three colitis/enteritis, one hepatitis). Most common CT features of colitis/enteritis included mesenteric hyperemia (n = 15), bowel wall thickening (n = 13), mucosal hyperenhancement (n = 10), and fluid-filled colon (n = 9).
CONCLUSION: Abdominal irAEs were detected on CT in 13% of NSCLC patients treated with nivolumab, and colitis, in the pancolitis form, was the most common irAE. Given the expanding role of immunotherapy, radiologists should be aware of the frequency and imaging manifestations of abdominal irAEs and the impact on patient management.
引用
- Alessandrino F, Sahu S, Nishino M, et al. Frequency and imaging features of abdominal immune-related adverse events in metastatic lung cancer patients treated with PD-1 inhibitor. Abdom Radiol (NY). 2019. PMID: 30790009. doi:10.1007/s00261-019-01935-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。